iBio (NASDAQ:IBIO) Stock Rating Lowered by Wall Street Zen

iBio (NASDAQ:IBIO – Get Free Report) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report released on Sunday, Wall Street Zen reports.

A number of other research firms have also weighed in on IBIO. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of iBio in a research report on Monday, September 21st. HC Wainwright initiated coverage on iBio in a research note on Thursday, September 17th. They set a “buy” rating and a $7.00 target price for the company. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $6.00.

Check Out Our Latest Report on IBIO

iBio Stock Performance

IBIO stock opened at $0.82 on Friday. iBio has a one year low of $0.68 and a one year high of $3.82. The company has a market capitalization of $57.78 million, a PE ratio of -2.93 and a beta of 1.47. The company’s fifty day moving average price is $0.93 and its 200-day moving average price is $1.59.

iBio (NASDAQ:IBIO – Get Free Report) last posted its earnings results on Tuesday, November 10th. The company reported ($0.05) EPS for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.02. The business had revenue of $1.07 million during the quarter, compared to analysts’ expectations of $0.03 million. On average, research analysts predict that iBio will post -0.36 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the business. Readystate Asset Management LP purchased a new position in shares of iBio during the third quarter worth about $26,000. Landscape Capital Management L.L.C. purchased a new stake in shares of iBio in the 3rd quarter valued at about $105,000. R Squared Ltd acquired a new stake in shares of iBio in the 3rd quarter valued at about $29,000. Squarepoint Ops LLC acquired a new stake in shares of iBio in the 2nd quarter valued at about $873,000. Finally, Headlands Technologies LLC boosted its position in shares of iBio by 333.0% in the 2nd quarter. Headlands Technologies LLC now owns 47,413 shares of the company’s stock valued at $83,000 after purchasing an additional 36,463 shares during the period. Hedge funds and other institutional investors own 7.90% of the company’s stock.

About iBio

(Get Free Report)

iBio, Inc. is a biotechnology company focused on using artificial intelligence and other computational tools to discover and develop therapies. Its research has included programs targeting obesity and metabolic diseases, as well as oncology. The company’s current approach builds on its earlier work in biologics manufacturing. Historically, iBio used its plant-based FastPharming platform to produce proteins and antibodies for research and therapeutic development. iBio is based in the United States and has shifted its focus from plant-based biologics production toward AI-enabled drug discovery.

Featured Stories

Analyst Recommendations for iBio (NASDAQ:IBIO)

Receive News & Ratings for iBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iBio and related companies with MarketBeat.com's FREE daily email newsletter.